Your browser doesn't support javascript.
loading
Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Earl, Helena M; Hiller, Louise; Howard, Helen C; Dunn, Janet A; Young, Jennie; Bowden, Sarah J; McDermaid, Michelle; Waterhouse, Anna K; Wilson, Gregory; Agrawal, Rajiv; O'Reilly, Susan; Bowman, Angela; Ritchie, Diana M; Goodman, Andrew; Hickish, Tamas; McAdam, Karen; Cameron, David; Dodwell, David; Rea, Daniel W; Caldas, Carlos; Provenzano, Elena; Abraham, Jean E; Canney, Peter; Crown, John P; Kennedy, M John; Coleman, Robert; Leonard, Robert C; Carmichael, James A; Wardley, Andrew M; Poole, Christopher J.
Afiliación
  • Earl HM; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Cambridge UK; NIHR Cambridge Biomedical Research Centre, Cambridge, UK; Cambridge Breast Cancer Research Unit, Cambridge, UK. Electronic address: hme22@cam.ac.uk.
  • Hiller L; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Howard HC; Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, UK.
  • Dunn JA; Warwick Clinical Trials Unit, University of Warwick, Coventry, UK.
  • Young J; Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Bowden SJ; Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • McDermaid M; Scottish Clinical Trials Research Unit, NHS Natio nal Services Scotland, Edinburgh, UK.
  • Waterhouse AK; Leeds Institute for Clinical Trials Research, University of Leeds, Leeds, UK.
  • Wilson G; The Christie NHS Foundation Trust, Manchester, UK.
  • Agrawal R; Department of Oncology, Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK.
  • O'Reilly S; Department of Oncology, Clatterbridge Cancer Centre, Wirral, UK.
  • Bowman A; Edinburgh Cancer Centre, Western General Hospital, Edinburgh, UK.
  • Ritchie DM; Department of Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Goodman A; Exeter Oncology Centre, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK.
  • Hickish T; Department of Oncology, Poole Hospital, Poole Hospital NHS Foundation Trust/Bournemouth University, Poole, Dorset, UK.
  • McAdam K; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Edith Cavell Campus, Peterborough City Hospital, Peterborough and Stamford Hospitals NHS Foundation Trust, Peterborough, UK.
  • Cameron D; Cancer Research UK Edinburgh Centre, MRC Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh, UK.
  • Dodwell D; Institute of Oncology, St James's University Hospital, Leeds Teaching Hospital NHS Trust, Leeds, UK.
  • Rea DW; Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
  • Caldas C; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Cambridge UK; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, University of Cambridge, Cambridge UK; NIHR Cambridge Biomedical Research Centre, Cambridge, UK; Cambridge Breast Cancer Research Unit, Cambridge, UK.
  • Provenzano E; NIHR Cambridge Biomedical Research Centre, Cambridge, UK; Department of Histopathology, Cambridge, UK.
  • Abraham JE; Department of Oncology, Addenbrooke's Hospital, University of Cambridge, Cambridge UK; NIHR Cambridge Biomedical Research Centre, Cambridge, UK; Cambridge Breast Cancer Research Unit, Cambridge, UK.
  • Canney P; Cancer Clinical Trials Unit (CaCTUS), Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Crown JP; Department of Medical Oncology, St Vincent's University Hospital, Dublin, Ireland.
  • Kennedy MJ; Cancer Trials Ireland (formerly ICORG), Dublin, Ireland.
  • Coleman R; Academic Unit of Clinical Oncology, Weston Park Hospital, Sheffield, UK.
  • Leonard RC; Department of Surgery and Cancer, Charing Cross Hospital, Imperial College London, London, UK.
  • Carmichael JA; Celgene, Research and Development, San Diego, CA, USA.
  • Wardley AM; NIHR/CRUK Christie Clinical Research Facility, Manchester, UK.
  • Poole CJ; Arden Cancer Research Centre, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
Lancet Oncol ; 18(6): 755-769, 2017 06.
Article en En | MEDLINE | ID: mdl-28479233
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2017 Tipo del documento: Article